Literature DB >> 9797252

Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase.

G Tachedjian1, M French, J Mills.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) isolates obtained from a patient with AIDS were assessed for coresistance to foscarnet and zidovudine. An HIV-1 strain (AP20) coresistant to foscarnet and zidovudine was isolated after 20 months of continuous combination therapy. The reverse transcriptase (RT) gene of AP20 had 41 substitutions which were different from the HXB2-D sequence and 9 that were different from the sequence of its foscarnet-sensitive, zidovudine-resistant progenitor virus (AP6). Six of these mutations were nonpolymorphic (T39A, V108I, K166R, K219R, K223Q, and L228R). Both strains had the conventional mutations mediating zidovudine resistance. In vivo selection may result in HIV-1 strains that are coresistant to foscarnet and zidovudine, but coresistance appears to require a complex evolutionary path and multiple RT mutations.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9797252      PMCID: PMC105992     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.

Authors:  S Safrin; C Crumpacker; P Chatis; R Davis; R Hafner; J Rush; H A Kessler; B Landry; J Mills
Journal:  N Engl J Med       Date:  1991-08-22       Impact factor: 91.245

2.  Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection.

Authors:  S Safrin; T G Berger; I Gilson; P R Wolfe; C B Wofsy; J Mills; K K Biron
Journal:  Ann Intern Med       Date:  1991-07-01       Impact factor: 25.391

3.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

Authors:  S Harada; Y Koyanagi; N Yamamoto
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

4.  In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus.

Authors:  M M Medveczky; E Horvath; T Lund; P G Medveczky
Journal:  AIDS       Date:  1997-09       Impact factor: 4.177

5.  Activation of a beta-galactosidase recombinant provirus: application to titration of human immunodeficiency virus (HIV) and HIV-infected cells.

Authors:  D Rocancourt; C Bonnerot; H Jouin; M Emerman; J F Nicolas
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

6.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Authors:  B A Larder; G Darby; D D Richman
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

7.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

Authors:  B A Larder; S D Kemp
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

8.  Impaired fitness of foscarnet-resistant strains of human immunodeficiency virus type 1.

Authors:  G Tachedjian; J W Mellors; H Bazmi; J Mills
Journal:  AIDS Res Hum Retroviruses       Date:  1998-08-10       Impact factor: 2.205

9.  Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.

Authors: 
Journal:  N Engl J Med       Date:  1992-01-23       Impact factor: 91.245

10.  Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial.

Authors:  K S Erlich; M A Jacobson; J E Koehler; S E Follansbee; D P Drennan; L Gooze; S Safrin; J Mills
Journal:  Ann Intern Med       Date:  1989-05-01       Impact factor: 25.391

View more
  3 in total

1.  Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance.

Authors:  J L Hammond; D L Koontz; H Z Bazmi; J R Beadle; S E Hostetler; G D Kini; K A Aldern; D D Richman; K Y Hostetler; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Development of Human Immunodeficiency Virus Type 1 Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains.

Authors:  Maria E Cilento; Aaron B Reeve; Eleftherios Michailidis; Tatiana V Ilina; Eva Nagy; Hiroaki Mitsuya; Michael A Parniak; Philip R Tedbury; Stefan G Sarafianos
Journal:  Antimicrob Agents Chemother       Date:  2021-09-13       Impact factor: 5.191

3.  Relationship between 3'-azido-3'-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Peter R Meyer; Suzanne E Matsuura; Dianna Zonarich; Rahul R Chopra; Eric Pendarvis; Holly Z Bazmi; John W Mellors; Walter A Scott
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.